Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dickson

Showing results (561-570 of 623) with videos related to

Pageof 63
Sort By:
Oncotarget|March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibitionMarta Kovatcheva, David D Liu, Mark A Dickson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumoursMaja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
British Journal of Cancer|July 10, 2020
Early treatment-related neutropenia predicts response to palbociclibNicholas P McAndrew, Mark A Dickson, Amy S Clark, et al.
British Journal of Cancer|October 10, 2013
High-risk features in radiation-associated breast angiosarcomasS P D'Angelo, C R Antonescu, D Kuk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated LiposarcomaChristina V Angeles, Ana Velez, Jordan Rios, et al.
Cancer Research|March 13, 2020
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for SurvivalGeorge Z Li, Tomoyo Okada, Young-Mi Kim, et al.
Sarcoma|June 18, 2016
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine LeiomyosarcomaA N Shoushtari, J Landa, D Kuk, et al.
Nature Communications|September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcomaJoonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumorsDana Rathkopf, Mark A Dickson, Darren R Feldman, et al.
JAMA Oncology|April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical TrialMark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Pageof 63

Showing results (561-570 of 623) with videos related to

Sort By:
Pageof 63
Oncotarget|March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibitionMarta Kovatcheva, David D Liu, Mark A Dickson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumoursMaja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
British Journal of Cancer|July 10, 2020
Early treatment-related neutropenia predicts response to palbociclibNicholas P McAndrew, Mark A Dickson, Amy S Clark, et al.
British Journal of Cancer|October 10, 2013
High-risk features in radiation-associated breast angiosarcomasS P D'Angelo, C R Antonescu, D Kuk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated LiposarcomaChristina V Angeles, Ana Velez, Jordan Rios, et al.
Cancer Research|March 13, 2020
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for SurvivalGeorge Z Li, Tomoyo Okada, Young-Mi Kim, et al.
Sarcoma|June 18, 2016
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine LeiomyosarcomaA N Shoushtari, J Landa, D Kuk, et al.
Nature Communications|September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcomaJoonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumorsDana Rathkopf, Mark A Dickson, Darren R Feldman, et al.
JAMA Oncology|April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical TrialMark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Pageof 63